Criteria for Acceptable Dietary Intake Biomarkers.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 10 03 2022
revised: 17 03 2022
accepted: 17 03 2022
entrez: 1 6 2022
pubmed: 2 6 2022
medline: 3 6 2022
Statut: ppublish

Résumé

Dietary intake biomarkers that can be written as actual intake, plus 'error' that is independent of actual intake and confounding factors can substitute for actual intake in disease association analyses. Also, such biomarkers can be used to develop calibration equations using self-reported diet and participant measures, and biomarker-calibrated intakes can be calculated in larger cohorts for use in disease association analyses. Criteria for biomarkers, and for biomarker-calibrated intakes, arise by working back from properties needed for valid disease association analyses. Accordingly, arguments for a potential biomarker are strengthened if error components are small relative to actual intakes, and important sources of reduced sensitivity or specificity are not apparent. Feeding study biomarker development can then involve regression of actual intake on putative biomarkers, with regression R2 values playing a role in biomarker evaluation. In comparison, 'predictive' biomarker status, as argued in this issue by Freedman and colleagues for 24-hour urinary sucrose plus fructose as biomarker for total sugars, involves regression of potential biomarker on actual intake and other variables, with parameter stability across populations and limited within-person variability as criteria. The choice of criteria for biomarkers and for biomarker-calibrated intakes, is discussed here, in the context of total sugars intake. See related article by Freedman et al., p. 1227.

Identifiants

pubmed: 35642392
pii: 699220
doi: 10.1158/1055-9965.EPI-22-0180
doi:

Substances chimiques

Biomarkers 0
Fructose 30237-26-4
Sucrose 57-50-1

Types de publication

Editorial Research Support, N.I.H., Extramural Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

1151-1153

Subventions

Organisme : NHLBI NIH HHS
ID : HHSN268201600001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600003C
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92021D00001
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201600004C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600002C
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA119171
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201600004C
Pays : United States

Commentaires et corrections

Type : CommentOn

Informations de copyright

©2022 American Association for Cancer Research.

Auteurs

Ross L Prentice (RL)

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Department of Biostatistics, University of Washington, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH